Tocilizumab to Help Prevent Cytokine Release Syndrome During Ramantamig Treatment for Multiple Myeloma
Tests one dose of tocilizumab versus placebo before ramantamig in relapsed or refractory multiple myeloma.
Key facts
- Who runs it
- Janssen Cilag International
- Where
- Alexandroupoli, Athens, Patras, Pireas, and Thessaloniki, GreeceSee the 7 sitesAlso in 5 other countries, 30 sites
- Trial code
- Registry title
- Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 123 people, planned
- Started
- 27 Aug 2026
- Expected to end
- 2 Dec 2030
- Type of study
- Interventional
- Record updated
- 11 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma that came back or stopped responding after at least 1 earlier treatment. It tests a single dose of tocilizumab against placebo before ramantamig.
- Age
- 18 years and older
- Sex
- All sexes can join.
- Disease stage
- Multiple myeloma that came back or did not respond to treatment, with disease that can be measured by blood or urine tests at screening.
- Earlier treatment
- At least 1 earlier line of treatment for myeloma. No other cancer treatment or investigational drug at the same time. After a donor stem cell transplant: at least 6 months since the transplant and off immunosuppressive drugs for 6 weeks.
- Biomarker or test result
- Measurable disease: serum M-protein level at least 0.5 g/dL, or serum free light chains at least 10 mg/dL with an abnormal ratio, or urine M-protein at least 200 mg/24 hours.
Main reasons for not taking part
- Active infection needing treatment with antiviral, antifungal or antibiotic drugs
- Active autoimmune disease needing immune-suppressing treatment within 6 months
- Heart attack, unstable angina, seizure, stroke or serious blood clot within 6 months
- Another active cancer or myelodysplastic syndrome, apart from a few low-risk exceptions
- Myeloma in the brain or its membranes, now or in the past
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Documented diagnosis of MM as defined by the criteria below: a. MM diagnosis according to the IMWG diagnostic criteria. b. Measurable disease at screening as assessed by local laboratory, defined by any of the following: i. Serum M-protein level ≥0.5 g/dL ii. Serum immunoglobulin FLC ≥10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio iii. Urine M-protein level ≥200 mg/24 hours
- Received at least 1 prior lines of antimyeloma therapy
- Relapsed or refractory disease as defined below: a. Relapsed disease is defined as an initial response to prior treatment, followed by confirmed PD by the IMWG response criteria >60 days after cessation of treatment. b. Refractory disease is defined as failure to achieve a response (ie, PR or better) or confirmed PD by the IMWG response criteria during previous treatment or ≤60 days after cessation of treatment
- Have an ECOG performance status score of 0 to 2 at screening and immediately before the start of study treatment administration (Oken 1982). Participants with ECOG PS 2 or 3 are eligible for the study if the ECOG PS score is related to stable physical limitations (eg, wheelchair-bound due to prior spinal cord injury) and not related to MM or associated therapy
Who cannot take part
- Concurrent use of any other anticancer treatment (including non-palliative radiotherapy) or investigational agent. For participants who received an allogeneic stem cell transplant, the transplant must be dated at least 6 months before first dose of study treatment. Participants who received an allogeneic transplant must be off all immunosuppressive medications for 6 weeks before the start of study treatment administration without signs of graft-versus-host disease.Toxicity related to prior anticancer treatment must have resolved to Grade 1 or better (except alopecia, skin fibrosis or discoloration, dry mouth, hearing loss, endocrinopathy managed with replacement therapy, peripheral neuropathy, which must be Grade 2 or better)
- Known active or prior CNS involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain MRI and lumbar cytology are required
- Serious underlying medical conditions, such as: a. Evidence of active systemic viral, fungal, or bacterial infection requiring systemic antiviral, antifungal, or antimicrobial therapy. b. Active autoimmune disease requiring systemic immunosuppressive therapy within 6 months before start of study treatment. EXCEPTION: Participants with vitiligo, Type I diabetes, or prior autoimmune thyroiditis that is currently euthyroid based on clinical symptoms and laboratory testing are eligible regardless of when these conditions were diagnosed or treatment. c. Overt clinical evidence of dementia or altered mental status d. Any of the following within 6 months prior to first dose of study treatment: severe or unstable angina, myocardial infarction, seizure, major thromboembolic events (eg, pulmonary embolism, cerebrovascular accident [including TIA and stroke]), clinically significant ventricular arrhythmias or heart failure New York Heart Association functional classification Class III to IV. Uncomplicated deep vein thrombosis is not considered exclusionary; Presence of any of the following: a. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM). b. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy. c. Any active malignancy other than MM that is considered at high risk of recurrence requiring systemic therapy. The only allowed exceptions are: i. Any active malignancy (ie, that was not progressing nor requiring treatment change in the last 24 months and not considered at high risk of recurrence requiring systemic therapy. ii. malignancies treated within the last 24 months that are considered at very low risk for recurrence: a) Non-muscle invasive bladder cancer (solitary Ta-papillary urothelial neoplasm of low malignant potential or low-Grade <3 cm, no carcinoma in situ). b) Non-melanoma skin cancers treated with curative therapy or localized melanoma treated with curative surgical resection alone. c) Non-invasive cervical cancer. d) Breast cancer: adequately treated lobular carcinoma in situ or ductal carcinoma in situ, or history of localized breast cancer (anti-hormonaltherapy is permitted). e) Localized prostate cancer (M0, N0) with a Gleason Score ≤7, treated locally only (Radical Prostatectomy/Radiotherapy/focal treatment). iii. Other malignancy that is considered cured with minimal risk of recurrence in consultation with the sponsor. NOTE: In the event of any questions, consult with the sponsor prior to enrolling a participant
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Which of these best describes your myeloma treatment so far?
- Has a doctor told you that your myeloma can be measured in your blood or urine tests?
- Has a doctor told you that you have myeloma in the brain or in the fluid and membranes around the brain and spinal cord, now or in the past?
Where in Greece
Also in 5 other countries, 30 sites
- University General Hospital of AlexandroupoliAlexandroupoli, GreeceTaking people
- 251 Air Force General HospitalAthens, GreeceTaking people
- General Hospital of Athens - AlexandraAthens, GreeceTaking people
- General University Hospital Of PatrasPatras, GreeceTaking people
- Metaxa Cancer Center Hospital Of PiraeusPireas, GreeceTaking people
- Hippokration HospitalThessaloniki, GreeceTaking people
- Theageneio Cancer HospitalThessaloniki, GreeceTaking people
About the trial
What the trial wants to find out
To determine if the addition of tocilizumab as prophylaxis compared to placebo will mitigate CRS by using a single dose of tocilizumab, prior to ramantamig dosing.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- Plain-language title
- Tocilizumab to Help Prevent Cytokine Release Syndrome During Ramantamig Treatment for Multiple MyelomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2025-524793-42-00, who can take part
- Record updated
- 11 September 2026